Experts contacted by NutraIngredients-USA​ said that activity in some categories of banned ingredients, such as DMAA and similar stimulants, seems to have receded.  But it’s unclear whether this is because the attempts by the US Food and Drug Administration to get this ingredient and other similar ingredients off the market may have had some actual deterrent effect.  Or, it could be that the market has just moved on to other ingredients with bigger sales potential.

DMAA (dimethylamylamine), a synthetic stimulant whose proponents claimed a natural source for the ingredient in geraniums, was once a huge seller.  It was taken off the market after having been liked to fatal cardiac events suffered by several young soldiers. At least in this instance, FDA’s efforts seems to have had some effect.

Rick Collins, an attorney with the firm Collins Gann McCloskey & Barry who specializes in sports nutrition and performance enhancing drug cases, said an informal poll of his client base has led him to conclude that DMAA is a ‘dead issue.’

Battle against SARMs

But he said the focus of the ‘edgy’ community then shifted to SARMs (selective androgen receptor modulators). These are chemicals that can mimic some of the effects of anabolic steroids without technically transgressing the law that banned the sales of those ingredients.  Subsequent regulations have addressed the SARMs issue specifically.

Efforts to shine a light on the SARMs epidemic extend back more than four years​. And still, Collins said, new SARMs cases continue to crop up.